Lantern Pharma Reports 2025 Financial Results

The biotech firm provided updates on its drug pipeline and financial performance.

Mar. 31, 2026 at 5:13pm

Got story updates? Submit your updates here. ›

An extreme close-up of gears, pipes, and other industrial pharmaceutical manufacturing equipment, captured in high contrast with dramatic shadows and highlights, conceptually representing the technical challenges of drug development.Lantern Pharma's financial results and pipeline updates highlight the technical complexity of modern drug development.Dallas Today

Lantern Pharma, a clinical-stage biopharmaceutical company, has reported its financial results for the fourth quarter and full year of 2025. The company also provided updates on its drug development pipeline and business operations.

Why it matters

As a clinical-stage biotech firm, Lantern Pharma's financial performance and pipeline progress are closely watched by investors and the pharmaceutical industry. The company's ability to advance its drug candidates through clinical trials and towards potential regulatory approvals is crucial for its long-term growth and success.

The details

In its Q4 2025 report, Lantern Pharma highlighted several key developments, including the initiation of a new Phase 2 clinical trial for its lead drug candidate, LP-100, and the expansion of its partnership with a major pharmaceutical company. The company also reported a net loss of $25 million for the quarter, which was in line with its guidance.

  • Lantern Pharma reported its Q4 2025 and full-year 2025 financial results on March 31, 2026.
  • The company initiated a new Phase 2 clinical trial for its lead drug candidate, LP-100, during the fourth quarter of 2025.

The players

Lantern Pharma

A clinical-stage biopharmaceutical company focused on developing novel cancer therapies.

Got photos? Submit your photos here. ›

What they’re saying

“We are pleased with the progress we made in 2025, including the initiation of a new Phase 2 trial for LP-100 and the expansion of our partnership. We remain focused on advancing our pipeline and delivering value for our shareholders.”

— Panna Sharma, CEO of Lantern Pharma

What’s next

Lantern Pharma plans to provide further updates on its drug development pipeline and financial performance in the coming quarters.

The takeaway

Lantern Pharma's 2025 financial results and pipeline updates demonstrate the company's continued progress in developing novel cancer therapies, which is crucial for its long-term growth and success in the competitive biotech industry.